Compare Moderna, Inc. (MRNA) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Materials Select Sector SPDR Fund — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Moderna, Inc. is far larger — about 10.2× Materials Select Sector SPDR Fund's market cap, and Moderna, Inc. is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| MRNA | XLB | |
|---|---|---|
Market Cap | $78.65B | $7.73B |
Volume | 37,373,437 | 13,681,146 |
Sector | Health | — |
52-Week High | $203.46 | $53.67 |
52-Week Low | $22.36 | $42.23 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
XLB trades at $49.27 with a slight 0.59% daily gain, though technical indicators signal bearish momentum with moving averages and ADX pointing lower. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets and top 10 holdings at 59% exposure. Recent analysis suggests much of the cyclical recovery appears priced in, limiting near-term upside potential despite infrastructure and manufacturing tailwinds.
The outlook remains cautious with technical weakness outweighing fundamental support. Investment opportunity exists in long-term materials exposure through efficient, low-cost ETF structure, but risks include sector concentration, cyclical pressures, and competition from AI-focused investments. Current levels near key support at $48-$49 require monitoring for potential breakdown.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
